JP2021531754A5 - - Google Patents
Info
- Publication number
- JP2021531754A5 JP2021531754A5 JP2021500735A JP2021500735A JP2021531754A5 JP 2021531754 A5 JP2021531754 A5 JP 2021531754A5 JP 2021500735 A JP2021500735 A JP 2021500735A JP 2021500735 A JP2021500735 A JP 2021500735A JP 2021531754 A5 JP2021531754 A5 JP 2021531754A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein according
- seq
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025002212A JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695627P | 2018-07-09 | 2018-07-09 | |
| US201862695623P | 2018-07-09 | 2018-07-09 | |
| US62/695,623 | 2018-07-09 | ||
| US62/695,627 | 2018-07-09 | ||
| US201962863710P | 2019-06-19 | 2019-06-19 | |
| US62/863,710 | 2019-06-19 | ||
| US201962864367P | 2019-06-20 | 2019-06-20 | |
| US62/864,367 | 2019-06-20 | ||
| US201962866420P | 2019-06-25 | 2019-06-25 | |
| US62/866,420 | 2019-06-25 | ||
| PCT/US2019/041085 WO2020014285A2 (en) | 2018-07-09 | 2019-07-09 | Fusion constructs and methods of using thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002212A Division JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531754A JP2021531754A (ja) | 2021-11-25 |
| JP2021531754A5 true JP2021531754A5 (enExample) | 2022-07-08 |
| JP7617839B2 JP7617839B2 (ja) | 2025-01-20 |
Family
ID=69141640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500735A Active JP7617839B2 (ja) | 2018-07-09 | 2019-07-09 | 融合構築物およびその使用法 |
| JP2025002212A Pending JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002212A Pending JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11535669B2 (enExample) |
| EP (1) | EP3820496A4 (enExample) |
| JP (2) | JP7617839B2 (enExample) |
| KR (1) | KR20210042909A (enExample) |
| CN (2) | CN112672753B (enExample) |
| AU (1) | AU2019301070B2 (enExample) |
| CA (1) | CA3105750A1 (enExample) |
| IL (1) | IL279965A (enExample) |
| SG (1) | SG11202100208VA (enExample) |
| WO (1) | WO2020014285A2 (enExample) |
| ZA (2) | ZA202100390B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US11771718B2 (en) * | 2017-10-18 | 2023-10-03 | Precigen, Inc. | Polypeptide compositions comprising spacers |
| WO2020127369A1 (en) * | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
| CN110734498A (zh) * | 2019-10-15 | 2020-01-31 | 上海科棋药业科技有限公司 | 一种用于解除免疫抑制的融合蛋白及其应用 |
| CN114616251B (zh) * | 2019-10-21 | 2024-05-24 | 南京维立志博生物科技有限公司 | 靶向PD-1和TGFβ的重组蛋白 |
| WO2021084124A1 (en) | 2019-11-01 | 2021-05-06 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| IL292758A (en) | 2019-11-05 | 2022-07-01 | Merck Patent Gmbh | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| EP4097220A4 (en) * | 2020-01-30 | 2024-03-20 | ImmunityBio, Inc. | ELIMINATION OF BCMA-POSITIVE MALIGNANCIES BY CAR-EXPRESSING NK CELLS |
| WO2021185337A1 (zh) * | 2020-03-20 | 2021-09-23 | 荣昌生物制药(烟台)股份有限公司 | 一种双特异性融合蛋白及其应用 |
| CA3175490A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Limited | Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| BR112022022020A2 (pt) * | 2020-04-29 | 2023-01-31 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Proteína bifuncional contra pd-1 e tgf-ss |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| CN113754771A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗pdl1×egfr的双特异性抗体 |
| JP2023532279A (ja) * | 2020-06-26 | 2023-07-27 | ソレント・セラピューティクス・インコーポレイテッド | 免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ） |
| WO2022011256A1 (en) * | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| CN116323658A (zh) * | 2020-09-28 | 2023-06-23 | 上海君实生物医药科技股份有限公司 | 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途 |
| US20230372319A1 (en) | 2020-11-02 | 2023-11-23 | Ares Trading S.A. | Combination Treatment of Cancer |
| AU2021372815A1 (en) | 2020-11-02 | 2023-06-22 | Ares Trading S.A. | Combination treatment of cancer |
| AU2021389989A1 (en) * | 2020-11-27 | 2023-06-08 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfβeta |
| KR20230146032A (ko) * | 2021-02-15 | 2023-10-18 | 다케다 야쿠힌 고교 가부시키가이샤 | Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법 |
| WO2022174451A1 (zh) * | 2021-02-22 | 2022-08-25 | 浙江道尔生物科技有限公司 | 一种具有抗癌活性的多结构域融合蛋白 |
| CN112979802B (zh) * | 2021-04-21 | 2021-08-03 | 上海普铭生物科技有限公司 | 抗人il-33单克隆抗体及其应用 |
| CN113249330A (zh) * | 2021-05-20 | 2021-08-13 | 深圳市先康达生命科学有限公司 | 免疫细胞及其应用 |
| EP4351640A1 (en) | 2021-06-07 | 2024-04-17 | Ares Trading S.A. | Combination treatment of cancer |
| JP2024532382A (ja) * | 2021-08-30 | 2024-09-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | アデノシンデアミナーゼの細胞表面発現を有するｔ細胞及びその使用 |
| KR20240050428A (ko) * | 2021-08-31 | 2024-04-18 | 더 텍사스 에이 앤드 엠 유니버시티 시스템 | 키메라 항원 수용체(car) t 세포 요법 플랫폼 |
| EP4396240A4 (en) * | 2021-09-03 | 2025-06-11 | Pulmongene (Hong Kong) Co., Limited | BIFUNCTIONAL FUSION PROTEIN AND USES THEREOF |
| WO2023086920A2 (en) * | 2021-11-12 | 2023-05-19 | Georgia Tech Research Corporation | Adenosine deaminase 2 compositions and methods for using same |
| WO2023125289A1 (zh) * | 2021-12-31 | 2023-07-06 | 上海宏成药业有限公司 | 抗pd-1抗体及其用途 |
| CN114540311A (zh) * | 2022-02-24 | 2022-05-27 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其应用 |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| EP0973888A1 (en) | 1997-02-06 | 2000-01-26 | Human Genome Sciences, Inc. | Dendritic cell-derived growth factor |
| NZ500284A (en) | 1997-04-18 | 2001-09-28 | Biogen Inc | Type II TGF-beta receptor fusion proteins |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2010020767A2 (en) * | 2008-08-21 | 2010-02-25 | Asterion Limited | Glp-1 fusion polypeptides |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20150086584A1 (en) | 2012-03-22 | 2015-03-26 | University Of Miami | Multi-specific binding agents |
| PL3489254T3 (pl) | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| WO2013169693A1 (en) * | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| AU2014309199B2 (en) * | 2013-08-20 | 2018-04-19 | Merck Sharp & Dohme Llc | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| CA2945388A1 (en) * | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
| BR112017007765B1 (pt) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| US20190048085A1 (en) | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| WO2018017144A1 (en) * | 2016-07-19 | 2018-01-25 | Brandeis University | Compositions and methods for identifying rna binding polypeptide targets |
| AU2017310027A1 (en) | 2016-08-12 | 2019-01-31 | Merck Patent Gmbh | Combination therapy for cancer |
| BR112019005964A2 (pt) | 2016-09-27 | 2019-06-18 | Epicentrx, Inc. | proteínas de fusão imunomoduladoras |
| WO2018129331A1 (en) | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
| ES2948647T3 (es) | 2017-05-04 | 2023-09-15 | Acceleron Pharma Inc | Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas |
| AU2018266103B2 (en) | 2017-05-09 | 2024-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies |
| MY202480A (en) | 2017-05-12 | 2024-04-30 | Shanghai hengrui pharmaceutical co ltd | Fusion protein containing tgf- receptor and medicinal uses thereof |
| MX2020011684A (es) * | 2018-05-04 | 2020-12-10 | Merck Patent Gmbh | Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer. |
| CN113226335B (zh) * | 2018-12-06 | 2023-10-13 | 广东天科雅生物医药科技有限公司 | 靶向肿瘤抗原、TGF-β、和免疫检查点的组合型TCR-T细胞疗法 |
| CN109913425B (zh) * | 2019-03-22 | 2021-05-11 | 中国人民解放军总医院第五医学中心 | 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用 |
| WO2020263796A1 (en) | 2019-06-23 | 2020-12-30 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Anti-alpp car-t cell therapy |
-
2019
- 2019-07-09 AU AU2019301070A patent/AU2019301070B2/en active Active
- 2019-07-09 SG SG11202100208VA patent/SG11202100208VA/en unknown
- 2019-07-09 CA CA3105750A patent/CA3105750A1/en active Pending
- 2019-07-09 EP EP19834221.4A patent/EP3820496A4/en active Pending
- 2019-07-09 KR KR1020217003783A patent/KR20210042909A/ko not_active Ceased
- 2019-07-09 JP JP2021500735A patent/JP7617839B2/ja active Active
- 2019-07-09 WO PCT/US2019/041085 patent/WO2020014285A2/en not_active Ceased
- 2019-07-09 CN CN201980058963.8A patent/CN112672753B/zh active Active
- 2019-07-09 CN CN202510846429.0A patent/CN120775065A/zh active Pending
- 2019-07-09 US US16/506,981 patent/US11535669B2/en active Active
-
2021
- 2021-01-05 IL IL279965A patent/IL279965A/en unknown
- 2021-01-19 ZA ZA2021/00390A patent/ZA202100390B/en unknown
-
2022
- 2022-11-23 US US18/058,364 patent/US20240141045A1/en active Pending
-
2023
- 2023-01-10 ZA ZA2023/00423A patent/ZA202300423B/en unknown
-
2025
- 2025-01-07 JP JP2025002212A patent/JP2025063123A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021531754A5 (enExample) | ||
| JP7450684B2 (ja) | 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法 | |
| Jin et al. | Emerging new therapeutic antibody derivatives for cancer treatment | |
| US11578131B2 (en) | Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules | |
| JP2025063123A5 (enExample) | ||
| US20180127502A1 (en) | Novel pd-1 immune modulating agents | |
| EP1786918A2 (en) | Novel tetravalent bispecific antibody | |
| CN101432015A (zh) | 功能性抗体 | |
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JP2019528683A (ja) | 多量体ｇｉｔｒ結合分子及びその使用 | |
| JP2021512151A5 (enExample) | ||
| JP2024518200A (ja) | Ｔ細胞リダイレクト治療薬及び抗ｃｄ４４治療薬を含む組成物 | |
| Müller et al. | Bispecific Antibodies | |
| CA3082036C (en) | MONOSPACTIC AND BISPACTIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION ROLE FOR CANCER TREATMENT | |
| JP2022512891A5 (enExample) | ||
| JP2021520201A (ja) | 抗ｃｄ２７抗体およびその使用 | |
| CA3147420A1 (en) | Anti-egfr/anti-4-1bb bispecific antibody and use thereof | |
| CA3207791A1 (en) | Anti-cd112r antibody and use thereof | |
| JP2024539630A5 (enExample) | ||
| Schaedel et al. | Antibodies and their fragments as anti-cancer agents | |
| TW202542198A (zh) | Cd137結合分子及其用途 | |
| Müller et al. | Bispecific antibodies | |
| EP4667491A1 (en) | Anti-cntn4 antibody and uses thereof | |
| WO2023178253A2 (en) | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy | |
| WO2024037628A1 (zh) | 一种双特异性抗体及其应用 |